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Abstract 
Metastases expressing tumor-specific receptors can be targeted and treated by binding of radiolabeled 
peptides (peptide receptor radionuclide therapy or PRRT). For example, patients with metastasized 
somatostatin receptor-positive neuroendocrine tumors (NETs) can be treated with radiolabeled 
somatostatin analogues, resulting in strongly increased progression-free survival and quality of life. 
There is nevertheless still room for improvement, as very few patients can be cured at this stage of 
disease. We aimed to specifically sensitize replicating tumor cells without further damage to healthy 
tissues. Thereto we investigated the DNA damaging effects of PRRT with the purpose to enhance these 
effects through modulation of the DNA damage response. Although PRRT induces DNA double strand 
breaks (DSBs), a larger fraction of the induced lesions are single strand breaks (expected to be similar to 
those induced by external beam radiotherapy) that require poly-[ADP-ribose]-polymerase 1 (PARP-1) 
activity for repair. If these breaks cannot be repaired, they will cause replication fork arrest and DSB 
formation during replication. Therefore, we used the PARP-1 inhibitor Olaparib to increase the number 
of cytotoxic DSBs. Here we show that this new combination strategy synergistically sensitized 
somatostatin receptor expressing cells to PRRT. We observed increased cell death and reduced cellular 
proliferation compared to the PRRT alone. The enhanced cell death was caused by increased numbers 
of DSBs that are repaired with remarkably slow kinetics, leading to genome instability. Furthermore, we 
validated the increased DSB induction after PARP inhibitor addition in the clinically relevant model of 
living human NET slices. We expect that this combined regimen can thus augment current PRRT 
outcomes. 
Key words: Neuroendocrine tumors, somatostatin receptor, peptide receptor radionuclide therapy, 
177Lu-DOTA-[Tyr3]octreotate, DNA damage response, combination treatment, PARP inhibitor 
Introduction 
Targeted anticancer therapies utilize specific 
molecular marks of the tumor to distinguish between 
tumor and normal healthy cells [1]. Neuroendocrine 
tumors (NET) overexpressing the somatostatin 
receptor subtype 2 (SSTR2) are target for treatment 
with radiolabeled peptides, called peptide receptor 
radionuclide therapy (PRRT) [2]. Clinical trials have 
successfully been finalized using the radionuclide 
Lutetium-177 (177Lu) coupled to somatostatin 
analogue DOTA-[Tyr3]octreotate (177Lu-DOTA-TATE) 
[3-5]. 177Lu-DOTA-TATE PRRT is currently applied as 
third line treatment and is the last hope for many 
patients suffering from metastasized neuroendocrine 
tumors. The results of clinical trials are favorable: high 
tumor response rates, low toxicity, extended 
progression-free survival and improved quality of life 
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[3-5]. Unfortunately, the overall efficacy analysis 
shows that most tumors that initially respond well to 
the treatment, will eventually relapse. Simply 
administering a higher radionuclide dose might lead 
to healthy tissue damage, especially in the bone 
marrow and kidneys, due to circulating radioactivity 
and renal clearance and reabsorption of radioactivity, 
respectively [6].  
The cell killing effect of 177Lu is likely to be due to 
DNA double strand breaks (DSBs) caused by the 
emitted ionizing beta particles. In recent years, 
increased knowledge of the DNA damage response 
(DDR) has been used to enhance anticancer therapies. 
A very attractive example is the use of 
poly-[ADP-ribose]-polymerase 1 (PARP-1) inhibitors 
to specifically kill cells with homologous 
recombination defects, e.g. Breast Cancer 1/2 
(BRCA1/2)-deficient cells: inactivation of a DNA 
repair pathway is compatible with survival of normal 
cells, but not with survival of repair-deficient cancer 
cells [7, 8]. Drugs such as PARP inhibitors are not only 
being applied as single agents, but can also be used in 
new strategies to enhance the efficacy of radiation [9]. 
These strategies aim at increasing the therapeutic 
window by sensitizing tumors and not the normal 
tissue. 
Many anticancer therapies are based on the 
well-described cytotoxicity of DSBs, produced by 
ionizing radiation or chemical agents, leading to 
tumor cell death. Next to DSBs, ionizing radiation 
produces less cytotoxic DNA lesions, such as base 
damage and DNA single-strand breaks (SSBs). 177Lu 
produces low energy transfer radiation and therefore 
the damage range is expected to be similar. PARP-1 
facilitates SSB-repair by activating and engaging 
repair enzymes at the site of the lesion. If the SSBs are 
not repaired efficiently (for example by blocking 
PARP-1 functioning), they will cause replication fork 
arrest and DSB formation in replicating cells. 
Therefore, PARP inhibition provides an excellent 
opportunity for tumor-specific radiosensitization of 
proliferating tumor cells, while sparing 
non-proliferating normal tissue [10]. We show that 
SSTR2-positive human osteosarcoma cells and ex vivo 
cultured human NET slices are synergistically 
sensitized to PRRT using the PARP inhibitor 
Olaparib. This sensitization is caused by increased 
genome instability leading to cell death. 
Material and Methods 
Cell lines and treatment 
Experiments were performed on human 
osteosarcoma cells (U2OS), U2OS cells stably 
expressing SSTR2 [11] and the SSTR positive rat 
pancreatic Ca20948 cells [12]. Cells were cultured in 
DMEM (Lonza), supplemented with 10% fetal bovine 
serum (Biowest), penicillin (50 units/mL) and 
streptomycin (50 µg/mL) (Sigma Aldrich), at 37°C 
and 5% CO2. 
For PRRT experiments, cells were treated for 4 h 
with different activity quantities of 177Lu-DTPA 
(saturated with DTPA) or 177Lu-DOTA-TATE (specific 
activity 53 MBq/nmol, radiometal incorporation 
>95% and radiochemical purity >90%) (IDB Holland). 
This specific activity is the same as used during 
patient treatment [5, 13]. Activity concentrations are 
based on a previous study by Capello and 
collaborators [14]. Subsequently, the radioligands 
were removed, cells were washed with phosphate 
buffered saline (PBS) (Lonza) and incubated in 
non-radioactive medium with or without 1 μM 
Olaparib (AZD2281, Ku-0059436) (Selleckchem). The 
Olaparib concentration was based on previous screens 
(data not shown) and we have used 1 μM because it 
had minimal effect as monotreatment on our cells. For 
comparative external beam irradiation experiments, 
cells were pretreated with 1 μM Olaparib for 4 h and 
subsequently irradiated with a Cesium-137 source 
(0.6Gy/min, Gammacell 40, Theratronics). 
All experiments were performed 2 or 3 times 
(with technical triplicates) and averages of 
experiments were plotted in the figures. In some 
figures, only 177Lu-DTPA and 177Lu-DOTA-TATE 
results are shown for simplicity. In these experiments, 
no difference was observed between non treated (NT) 
samples and 177Lu-DTPA treated samples. NT data 
can be found in the supplemental figures. 
Colony survival assay 
For measurement of cell killing, a colony 
survival was performed. U2OS, U2OS+SSTR2 or 
Ca20948 cells were seeded in 6-well plates (1×105 cells 
/ well) in 2 mL medium and the next day adherent 
cells were incubated for 4 h at 37°C, 5% CO2 with 
5×10-8 M / 5 MBq, 2×10-8 M / 2 MBq, 5×10-9 M / 0.5 
MBq or 2×10-9 M / 0.2 MBq 177Lu-DOTA-TATE or 
with 5 MBq, 2 MBq, 0.5 MBq or 0.2 MBq 177Lu-DTPA 
in 2 mL medium. Cells were trypsinized and seeded 
in triplicate in 6 well plates (300 cells per well) in 2 mL 
normal medium or medium containing 1 μM 
Olaparib. Four days after treatment, medium was 
replaced for 2 mL medium without Olaparib for all 
conditions. Ten days after treatment, colonies were 
washed with PBS and stained with 0.1% Coomassie 
blue acetic acid staining solution for 15 min at room 
temperature (RT). Colonies were counted manually 
and normalized to untreated controls (with or without 
1 μM Olaparib). The area under the curve was 
calculated using GraphPad Prism software. 
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Sulforhodamine beta assay 
For measurement of cell number a 
sulforhodamine beta assay was performed. 
U2OS+SSTR2 cells were seeded in 6-well plates (5×105 
cells / well) and the next day adherent cells were 
incubated for 4 h with 5×10-8 M / 5 MBq 
177Lu-DOTA-TATE or with 5 MBq 177Lu-DTPA. Cells 
were trypsinized and seeded in triplicate in 12 well 
plates (1.5×104 cells per well) in 1 mL normal medium 
or medium containing 1 μM Olaparib and allowed to 
grow for one to six days. Subsequently, medium was 
removed and cells were fixed with 1 mL 10% 
trichloroacetic acid overnight at 4oC. Plates were 
washed five times with tap water and dried. Then 
cells were incubated in 500 μl 0.5% sulforhodamine 
beta (SRB) in 1% acetic acid for 20 minutes at RT. 
Plates were washed four times with 1% acetic acid 
and air-dried. SRB was dissolved in 500 μl 10 mM Tris 
solution and absorbance was measured at 560 nm 
using a GloMax®-Multi Detection System (Promega).  
Immunofluorescent stainings cells 
For analysis of DDR and apoptosis parameters, 
different immunofluorescent stainings were 
performed. U2OS+SSTR2 cells were grown on glass 
coverslips in 6-well plates (DSB and micronuclei) or 
24-well plates (cytochrome c release) and were 
incubated for 4 h with 5×10-8 M / 5 MBq 
177Lu-DOTA-TATE or 5 MBq 177Lu-DTPA in 2 mL 
medium (DSB and micronuclei) or 500 μL medium 
(cytochrome C release) for 4 h at 37°C. Subsequently, 
cells were washed twice with PBS and incubated in 
normal medium or medium containing 1 μM Olaparib 
and allowed to grow until different timepoints (2 mL 
or 500 μL, respectively). For cytochrome C release 
quantification, 20 μM Q-VD-OPH (QVD, MP 
Biomedicals) was added until fixation to block the 
cells in early apoptosis. Cells were fixed with 1 mL 2% 
paraformaldehyde (Sigma Aldrich) for 15 min at RT, 
permeabilized for 20 min at RT in PBS containing 
0.1% Triton X-100 (Sigma Aldrich) and incubated in 
blocking buffer (PBS, 0.1% Triton X-100, 2% bovine 
serum albumin (Sigma Aldrich)) for 30 min at RT. 
Next, cells were incubated for 90 min at RT with the 
primary antibody, anti-53BP1 (NB100-304, Novus 
Biologicals, 1/1000) or anti-cytochrome C (556432, BD 
Biosciences 1/100) diluted in blocking buffer. 
Following incubation cells were washed with PBS 
0.1% Triton X-100 and incubated with the secondary 
antibody (goat anti-rabbit Alexa Fluor 594 or goat 
anti-mouse Alexa Fluor 488, Life Technologies; 
1/1000) in blocking buffer for 60 min at RT. Cells were 
washed with PBS and mounted with Vectashield 
containing DAPI (Vector Laboratories). 
For replication analysis, U2OS+SSTR2 cells were 
grown on glass coverslips in 24-well plates in 500 μL 
medium and 10 μM 5-ethynyl-2’-deoxyuridine (EdU) 
(Thermo Fisher Scientific) was added 1 h before 
fixation. Staining was performed according to 
manufacturer protocol (with Alexa fluor 594). 
Propidium iodide staining for cell cycle analysis 
For cell cycle distribution measurement, cells 
were grown in 6 well plates and incubated for 4 h 
with 5×10-8 M / 5 MBq 177Lu-DOTA-TATE or 5 MBq 
177Lu-DTPA in 2 mL medium. Subsequently, cells 
were washed twice with PBS and incubated in 2 mL 
normal medium or medium containing 1 μM 
Olaparib. Samples were harvested by trypsinization 3 
or 6 days after treatment. Following, cells were 
washed with PBS and fixed in 5 mL ice cold 70% 
ethanol. Cells were stored at -20oC until radioactivity 
was decayed. Cells were washed with PBS and 
permeabilized in 0.2% Triton X-100 in PBS for 5 min at 
RT. Subsequently cells were resuspended in 500 μL 
propidium iodide (PI) mix (50 μg/mL RNase (Roche) 
and 10 μg/mL PI (Sigma Aldrich) in PBS) and 
transferred to Fluorescence-activated cell sorting 
(FACS) tubes. Tubes were stored on ice for ~4 h until 
analysis. Cell cycle distribution was measured using a 
LSRFORTESSA FACS machine (BD Bioscience). 
Gating using the forward scatter and side scatter was 
used to discard aggregates and dead cells. PI was 
detected using the 610/20 bandpass emission filter. 
Ex vivo culturing of human NET slices and 
treatment 
For ex vivo assessment of PRRT, fresh pancreatic 
neuroendocrine tissue was obtained from patients 
undergoing surgery. After macroscopic investigation 
by the pathologist, remaining tumor tissue was used 
for storage in the biobank which includes use for 
research purposes. Tissue was obtained according to 
the code of proper secondary use of human tissue in 
the Netherlands established by the Dutch Federation 
of Medical Scientific Societies and approved by the 
local Medical Ethical committees. Specimens were 
coded anonymously in a way that they were not 
traceable to the patient by lab workers. Tissue samples 
were kept at 4oC and transported in DMEM/F12 
medium (Lonza), supplemented with 10% fetal 
bovine serum, penicillin (50 units/mL) and 
streptomycin (50 µg/mL). Tumor tissue was sliced in 
300 μm slices using a Leica VT 1200S Vibratome 
(vibration amplitude 3.0 mm and slicing speed 0.3 
mm/sec). Culturing was performed in Medium D 
(DMEM/F12 supplemented with 10% fetal bovine 
serum, penicillin (50 units/mL), streptomycin (50 
µg/mL), 0.3 µg/mL hydrocortisone (Sigma), 4 µg/mL 
insulin (Sigma), 8 ng/mL epidermal growth factor 
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(Sigma) and 7 ng/mL cholera toxin (Sigma) (adapted 
and optimized for NET slices from [15])), at 5% CO2 
and 37oC. Slices were cultured in 6 well plates and 
subjected to rotation at 60 rpm using a Stuart SSM1 
mini orbital shaker that was placed in the incubator. 
At different time point after treatment, slices were 
fixed in 10% neutral buffered formalin for 24 h at RT. 
Subsequently, tumor slices were embedded in 
paraffin and 4 μm sections from 2 different regions of 
the tumor slice were generated for staining and 
microscopy analysis. 
For PRRT experiments, slices were treated for 4 h 
with 5×10-9 M / 0.5 MBq 177Lu-DOTA-TATE or 0.5 
MBq 177Lu-DTPA in 2 mL medium D. Subsequently, 
the slices were removed from the medium, washed 
for 1 min in PBS and transferred to 3 mL 
non-radioactive medium D with or without 10 μM 
Olaparib in new 6 well plates. Slices were incubated 
for different timepoints (up to 4.5 days after 
treatment). 
Hematoxylin and eosin staining NET slices 
For histological analysis, paraffin sections were 
deparaffinized in xylene and subsequently 
rehydrated by incubation in decreasing 
concentrations of ethanol. Sections were incubated for 
1 min at RT in hematoxylin (Sigma Aldrich) followed 
by washing with tap water. Sections were incubated 
in eosin (Applichem) for 1 min at RT and 
subsequently dehydrated in increasing concentrations 
of ethanol. Before mounting with Entellan (Merck) 
sections were incubated in xylene. 
Immunofluorescent stainings NET slices 
For immunofluorescent 53BP1 staining, paraffin 
sections were deparaffinized in xylene and 
subsequently rehydrated by incubation in decreasing 
concentrations of ethanol. Target antigen retrieval 
was performed using a Target Retrieval Solution 
pH6.1 (Dako) for 18 min in a microwave at 650 W. 
Cells were permeabilized for 2×5 min at RT in PBS 
containing 0.1% Triton X-100 (Sigma Aldrich) and 
incubated in blocking buffer (PBS, 0.1% Triton X-100, 
2% bovine serum albumin (Sigma Aldrich)) for 30 min 
at RT. Sections were incubated with the primary 
antibody, anti-53BP1 (1/1000) in blocking buffer for 
90 min at RT. Subsequently, sections were washed 
with PBS 0.1% Triton X-100 and incubated with the 
secondary antibody (goat anti-rabbit Alexa Fluor 594, 
1/1000) in blocking buffer for 60 min at RT. Cells were 
washed with PBS and mounted with Vectashield 
containing DAPI. 
Imaging and analysis 
For DSB (cells and slices) and micronuclei 
quantification, Z-stack imaging was performed using 
a TCS SP5 confocal microscope (Leica) and foci were 
counted from at least 50 cells per condition per 
experiment (cells) or on average 650 cells per 
condition per slice (slices) using Image J software 
(settings: median blur 1.0, maximum projection and 
find maxima, noise tolerance 75 for cells and 100 for 
slices). Micronuclei of least 50 cells per condition per 
experiment were counted manually and expressed as 
fraction of cells with micronuclei. For cytochrome C 
release quantification, imaging was performed using 
a DM4000 fluorescent microscope (Leica). At least 50 
cells per condition per experiment were counted 
manually and expressed as fraction of cells with 
released cytochrome C (cytoplasmic and total release). 
For EdU staining, imaging was performed using a 
DM4000 fluorescent microscope and at least 100 cells 
per condition per experiment were analyzed. H&E 
stainings are image using the Olympus BX40 phase 
contrast microscope. Quantification data is presented 
as mean with standard error. 
Uptake assay 
U2OS+SSTR2 cells were seeded in 12-well plates 
in 1 mL medium and the next day adherent cells 
(~1×105 cells/ well) were incubated with 5×10-9 M/ 
0.25 MBq 177Lu-DOTA-TATE in 1 mL medium for 4 h 
at 37°C with 5% CO2. Subsequently, cells were 
washed with PBS. For day 0 measurements, the 
membrane-bound fraction was separated from the 
internalized fraction by incubating cells for 10 min in 
1 mL 50 mM glycine and 100 mM NaCl, pH2.8. Then, 
cells were lysed in 1 mL 0.1 M NaOH to collect the 
internalized fraction. For day 1-6 measurements, 
medium was added to the cells and they were 
incubated at 37°C, 5% CO2. For every time point, 
medium, membrane-bound fractions and internalized 
fractions were collected as described for day 0. All 
fractions were counted in a 1480 WIZARD automatic 
gamma counter (PerkinElmer). Data is expressed as 
percentage of added dose (%AD). Experiments were 
performed in triplicate and gamma-counter 
measurements were corrected for decay. 
Statistics 
Significance was determined using a 
homoscedastic 2-tailed student t-test. Samples were 
considered statistically different if p<0.05. * p<0.05, ** 
p<0.01 and *** p<0.001. 
Results 
PARP inhibition reduced cell number and 
proliferation after 177Lu-DOTA-TATE 
treatment 
Cancer cells are characterized by their fast 
growing potential and anticancer treatments affect 
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this via induction of apoptosis or inhibition of 
proliferation. Therefore, we examined whether 
inhibition of SSB-repair using the PARP inhibitor 
Olaparib affected cell number using a sulforhodamine 
beta (SRB) assay. Figure 1A shows that 
177Lu-DOTA-TATE treatment significantly lowered 
the number of cells compared to 177Lu-DTPA 
treatment (DTPA is a chelator and does not bind 
SSTR2). Combination treatment of 177Lu-DOTA-TATE 
plus PARP inhibitor further reduced cell growth rate 
by 2.5 fold at day 6 after treatment (Figure 1B) and 
even completely blocked growth from day 3 at least 
until day 6 after treatment. PARP inhibition alone 
inhibited cell growth in non-treated or 177Lu-DTPA 
treated cells by 2 fold. 
The total cell number is caused by a balance 
between cell death and proliferation. We therefore 
examined the effect of 177Lu-DOTA-TATE alone or 
combined with PARP inhibition on the cell cycle. EdU 
incorporation for 1 hour before fixation allowed 
quantification of S-phase cells (Figure 2A). Treatment 
with 177Lu-DOTA-TATE led to decreased replication 
from 1 to 4 days after exposure with 40-50%, which 
returned to normal levels at day 5. Combination 
treatment of 177Lu-DOTA-TATE with PARP inhibitor 
reduced the fraction of S-phase cells with 50% and this 
effect remained for at least 6 days after treatment. 
PARP inhibitor treatment alone did not significantly 
affect replication (Figure 2B and Figure S4A). The 
reduction of replication was caused by an increase of 
the number of cells in G2/M phase, as shown by 
propidium iodide (PI) FACS cell cycle analysis (Figure 
S1). 
PARP inhibition enhanced 177Lu-DOTA-TATE 
induced cell death 
The SRB assay showed a stabilization of the total 
cell population after the combination treatment of 
177Lu-DOTA-TATE and PARP inhibitor. However, the 
EdU incorporation and PI assays showed a reduction, 
but not the complete absence of proliferation. This 
indicates that proliferation and cell death are in 
equilibrium. Therefore, we further investigated the 
effect of the combination treatment on cell death. 
Clonal survival experiments showed the specific cell 
killing by 177Lu-DOTA-TATE compared to 
177Lu-DTPA treatment in both U2OS+SSTR (Figure 
3A,B) and Ca20948 (Figure S2C,D) cells. U2OS cells 
without SSTR2 expression were not killed by 
177Lu-DOTA-TATE treatment (Figure S2A,B), 
confirming the specificity of the 
treatment. Next, we investigated 
whether addition of the PARP inhibitor 
could specifically sensitize the 
SSTR2-positive U2OS cells. Combination 
treatment of 177Lu-DOTA-TATE and 
PARP inhibitor indeed significantly 
decreased the cellular survival 
compared to 177Lu-DOTA-TATE alone 
(reduction of 50% of the area under the 
curve), while PARP inhibition did not 
sensitize cells treated with 177Lu-DTPA 
(Figure 3A,B). 
We then analyzed whether 
apoptosis was increased after 
combination treatment via measurement 
of cytochrome C release from the 
mitochondria into the cytoplasm (early 
step during apoptosis) (Figure 3C) [16]. 
The caspase inhibitor Q-VD-OPh was 
added to the cells directly after PRRT to 
block completion of apoptosis (step after 
cytochrome C release) and prevent cell 
detachment from the cell culture surface, 
enabling direct determination of 
accumulating apoptotic cells. As 
expected, 177Lu-DOTA-TATE treatment 
induced apoptosis over time. Consistent 
with the survival experiment, a 
significantly steeper increase in 
 
Figure 1. Effect of PARP inhibition on cell number after PRRT. (A) SRB assay; the absorbance in 
arbitrary units (a.u.) correlates with the relative number of cells. Cells were non-treated (NT) or 
treated with 177Lu-DTPA or 177Lu-DOTA-TATE and afterwards treated or not with PARP inhibitor 
(PARPi) and measured in triplicate at different time points after treatment. Error bars indicate the 
SEM. (B) Ratio of NT, 177Lu-DTPA or 177Lu-DOTA-TATE treated cells without/with PARPi. Error 
bars indicate the SEM. 
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apoptosis was observed in cells treated with the 
combined treatment of 177Lu-DOTA-TATE and PARP 
inhibitor compared to 177Lu-DOTA-TATE alone (2.3 
fold at 3 days after treatment) (Figure 3D). 
Cytotoxicity is largely dependent on the 
absorbed dose, and thus on the quantity of 
radionuclide taken up by the cells. In order to exclude 
that the increased cell death might have been caused 
by increased radionuclide uptake after PARP 
inhibition, we determined membrane bound, 
internalized and medium (excreted plus released) 
radioactive fractions over time after PRRT in cells 
treated with and without PARP inhibitor (Figure S3). 
As we did not observe any difference between the two 
conditions, the increased cell death was not caused by 
the effect of the PARP inhibitor on radionuclide 
uptake/residence time, implying that a direct effect 
on the DDR is indeed the most likely explanation for 
its sensitizing effect. 
 
 
Figure 2. Effect of PARP inhibition on proliferation after PRRT.(A) Immunofluorescent EdU (red) and DAPI (blue) staining of a field of cells at T=3 days and T=6 days 
after treatment. Cells were non-treated (NT), treated with 177Lu-DTPA or with 177Lu-DOTA-TATE and afterwards treated or not with PARPi. Scale bar = 15 μm. (B) 
Quantification of the number of EdU positive cells at different time points after treatment. 8 microscope fields with on average 15 cells per field were quantified. Error 
bars represent the SEM and statistics represent the comparison between 177Lu-DOTA-TATE and 177Lu-DOTA-TATE + PARPi. Not significant (ns), * p<0.05, ** 
p<0.01 and *** p<0.001. NT data can be found in Figure S4A. 
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Figure 3. Effect of PARP inhibition on PRRT induced cell death.(A) Colony forming ability of cells after different activity quantities of PRRT (177Lu-DTPA or 
177Lu-DOTA-TATE) and afterwards treated or not with PARP inhibitor (PARPi). The percentage of surviving cells was plotted against the applied PRRT activity, 
measured by counting surviving colonies of two independent experiments. Error bars indicate the SEM. (B) Area under the curve comparison from the data in panel 
3A. Statistics: not significant (ns), ** p<0.01 and *** p<0.001. (C) Immunofluorescent cytochrome C (green) and DAPI (blue) staining of a field of cells 3 days after 
treatment. Cells with released cytochrome C were are marked with an asterisk. Cells were non-treated (NT), treated with 177Lu-DTPA or with 177Lu-DOTA-TATE 
and afterwards treated or not with PARPi. Scale bar = 15 μm. (C) Quantification of the number of cells with released cytochrome C at 1, 2 and 3 days after treatment. 
8 microscope fields with on average 17 cells per field were quantified. Error bars represent the SEM. Statistics: not significant (ns), ** p<0.01 and *** p<0.001. 
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PARP inhibition increased the number and 
persistence of DNA double strand breaks after 
177Lu-DOTA-TATE treatment 
The underlying cause of enhanced cell death 
after PARP inhibition is probably a difference in DNA 
damage induction and/or repair. Therefore, we 
determined the spatiotemporal distribution of DSBs 
after therapy. Accumulation of p53-binding protein 1 
(53BP1) at DSB sites (so-called foci, Figure 4A) is a 
biomarker of radiation-induced DSBs, which has been 
used to monitor DNA damage and repair in a wide 
range of applications (reviewed in [17]). Figure 4 
shows the timing and level of DSB induction and 
repair after PRRT by measuring the number of 53BP1 
foci per nucleus. 177Lu-DOTA-TATE treatment of 
SSTR2-positive cells induced many DSBs which 
remained present for 3 days, whereas unbound 
177Lu-DTPA only caused transient DSBs (Figure 4B 
and Figure S4B). Combination of 177Lu-DOTA-TATE 
treatment with PARP inhibition not only led to an 
increased number of DSBs at all time points, but 
surprisingly these DSBs were also present up to 6 
days after 177Lu-DOTA-TATE treatment in the 
presence of PARP inhibitor, whereas DSBs were 
repaired at 4 days after treatment in the absence of 
PARP inhibition (Figure 4B). Cells treated with PARP 
inhibitor alone showed a small increase of DSBs, but 
this effect was minimal (Figure S4B). 
Ideally, one would prefer to minimize the time of 
patient PARP inhibitor treatment after PRRT. 
Therefore, we adapted the experiment such that the 
PARP inhibitor was removed at day 4 after treatment. 
Interestingly, cells treated with 177Lu-DOTA-TATE 
and PARP inhibitor for 4 days did not show a 
decrease in the number of DSBs when the PARP 
inhibitor was removed from the medium (Figure 4C), 
implying that a short interval of PARP inhibitor 
treatment may suffice to reach optimal tumor 
sensitization. 
Theoretically, an increase of DSBs after PARP 
inhibition would only be expected in replicating cells, 
as they are expected to result from replication forks 
that encounter a single strand break. Therefore, cells 
were pretreated with PARP inhibitor and then 
exposed to an acute dose of ionizing radiation 
(external beam irradiation or XRT). Replicating cells 
were visualized by staining of the incorporated 
thymidine analogue 5-ethynyl-2’-deoxyuridine (EdU). 
XRT induced DSBs equally in replicating- and 
non-replicating cells. However, combination of XRT 
and PARP inhibition significantly increased the 
number of DSBs in replicating cells and not in 
non-replicating cells, indicating that a cell needs to go 
through replication for the PARP inhibitor to function 
as a sensitizer (Figure 4D). 
Increased genomic instability after 
combination of 177Lu-DOTA-TATE treatment 
with PARP inhibition 
Unrepaired DSBs may result in chromosome 
damage, leading to micronuclei formation. 
Micronuclei are extra-nuclear bodies that contain 
whole chromosomes or damaged chromosome 
fragments that were not incorporated into the nucleus 
after cell division (reviewed in [18]). In line with DSB 
induction, 177Lu-DOTA-TATE treatment led to an 
increased number of cells with micronuclei up to 4 
days after treatment (Figure 4E and Figure S4C). As 
expected from transient DSB induction, 177Lu-DTPA 
treatment only caused a temporary increase in cells 
with micronuclei one day after treatment. Again, 
combination of 177Lu-DOTA-TATE treatment with 
PARP inhibition boosted the fraction of cells with 
micronuclei at later time points up to 6 days after 
treatment. Remarkably, not only the fraction of cells 
with micronuclei increased, but also the number of 
micronuclei per cell, especially at the later time points 
(Figure S5). 
PARP inhibition increased the number of DNA 
double strand breaks after 177Lu-DOTA-TATE 
treatment in ex vivo cultured NET slices 
The in vitro studies mentioned above have 
clearly shown that PARP inhibition can sensitize SSTR 
positive cells to PRRT. As several key parameters of 
tumors differ considerably from cells grown in 
2D-culture (such as morphology and heterogeneity), 
we took the analysis of the DDR to the next level by 
using patient-derived NET-tissue (Figure 5A). As 
shown previously in cell cultures, tumor slices treated 
with 177Lu-DOTA-TATE showed an increase in the 
number of 53BP1 foci per nucleus, while treatment 
with 177Lu-DTPA did not induce DSBs (data not 
shown). Again, PARP inhibitor was able to further 
increase the number of 53BP1 foci induced by 
177Lu-DOTA-TATE (Figure 5B,C). The tumor slices 
were examined up to 4.5 days after dissection (and 
177DOTA-TATE treatment), but this timeframe was 
too short to observe effects on replication and 
apoptosis (data not shown). 
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Figure 4. Effect of PARP inhibition on double-strand break induction and genomic instability after PRRT. (A) Representative cells with immunofluorescent 53BP1 
(red) and DAPI (blue) staining at 3 time points after treatment (0 hours, 3 days and 6 days). Cells were non-treated (NT), treated with 177Lu-DTPA or with 
177Lu-DOTA-TATE and afterwards treated or not with PARP inhibitor (PARPi). Scale bar = 5 μm. (B) Quantification of 53BP1 foci of at least 50 cells per condition 
at different time points after treatment. Error bars represent the SEM. Statistics represent the comparison between 177Lu-DOTA-TATE and 177Lu-DOTA-TATE + 
PARPi. *** p<0.001. NT data can be found in Figure S4B. (C) Quantification of 53BP1 foci of at least 50 cells per condition of cells treated with 177Lu-DOTA-TATE 
and PARPi for 4 days. Following cells were treated or not with PARPi for different time points. Error bars represent the SEM. (D) Quantification of 53BP1 foci of at 
least 60 cells per condition of cells treated with or without PARPi combined or not with ionizing radiation exposure of 2 Gy (XRT). Cells were incubated with EdU 
directly after XRT and fixed 1 hour later to determine which cells were replicating at the time of radiation exposure. Error bars represent the SEM. Statistics: not 
significant (ns) and *** p<0.001. (E) Quantification of the number of cells with micronuclei. 10 microscope fields with on average 13 cells per field were quantified. 
Error bars represent the SEM and statistics represent the comparison between 177Lu-DOTA-TATE and 177Lu-DOTA-TATE + PARPi. ** p<0.01 and *** p<0.001. NT 
data can be found in Figure S4C and detailed quantifications can be found in Figure S5.  
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Figure 5. Effect of PARP inhibition on double-strand break induction after PRRT in ex vivo cultured NET slices. (A) Hematoxylin and eosin staining of the fresh 
neuroendocrine pancreatic tumor; islands of NET cells are surrounded by stromal cells. (B) Immunofluorescent staining of 53BP1 (red) and DAPI (blue) of a field of 
cells at 2 time points after treatment (0 days and 3.5 days after treatment). Tissue slices were non-treated (NT) or treated with 177Lu-DOTA-TATE and afterwards 
treated or not with PARP inhibitor (PARPi). Scale bar = 5 μm. (C) Quantification of 53BP1 foci of different fields of cells at 2 locations per tumor slice of on average 
660 cells per condition at different timepoints after treatment. Error bars represent the SEM. Statistics represent the comparison between 177Lu-DOTA-TATE and 
177Lu-DOTA-TATE + PARPi. * p<0.05 and ** p<0.01. 
 
Discussion 
We explored the effect of combining PRRT with 
PARP inhibitors to sensitize tumor cells by increasing 
the number of cytotoxic DSBs. PARP inhibitors are 
associated with relatively mild side effects in the clinic 
when applied as a monotherapy [19] and are therefore 
ideal candidates for the use as combination agents. 
We showed that PARP inhibition synergistically 
sensitized SSTR2-expressing human tumor cells to 
177Lu-DOTA-TATE treatment. This combination 
treatment reduced cell numbers and replication and 
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induced cell death. The underlying mechanism is the 
inability to repair PRRT-induced SSBs that will be 
converted into DSBs during replication. Indeed we 
observed a vast increase in the number of DSBs that 
persisted over time, even when the PARP inhibitor 
was removed from the cells. As expected, this led to 
increased genome instability. An increase in the 
number of DSBs after combination treatment 
compared to 177Lu-DOTA-TATE treatment alone was 
also observed in ex vivo cultured NET slices. The 
innovating strategy of using PARP inhibitors to 
sensitize SSTR2-expressing tumor cells to PRRT has 
great potential to enhance the PRRT therapeutic 
index. 
Several other studies have been performed to 
sensitize tumors to chemotherapeutics and 
radiotherapy using inhibitors of the DDR such as 
PARP inhibitors (reviewed in [9]). These approaches 
seem favorable in reducing tumor cells growth, but 
they are accompanied by significant damage to 
normal tissue. Several organs express (low levels) of 
the SSTR2, such as the pancreas, lung and cerebellum 
[20], which might be expected to acquire DNA 
damage by PRRT, as well. However, PARP inhibition 
only increases the number of DSBs in proliferating 
cells, as a result of replication through SSBs. Extra 
sensitization via PARP inhibition of the 
SSTR2-positive organs is therefore not to be expected, 
because little proliferation takes place in the adult 
organism. SSTR2 are also present on a small subset 
(<1%) of human bone marrow cells [20], however our 
experiments shows undetectable uptake of 
177Lu-DOTA-TATE in the bone marrow (data not 
shown). Nonetheless, sensitization of the bone 
marrow by concomitant PARP inhibition might be 
expected, as they are proliferative, therefore close 
monitoring of bone marrow damage is essential. To 
minimize sensitization of bone marrow and 
non-targeted proliferative tissue, optimal timing for 
the combination treatment is essential. All unbound 
(circulating) 177Lu-DOTA-TATE needs to be cleared 
from the body before PARP inhibition treatment is 
initiated. As SSBs are generally repaired in the first 
few minutes after radionuclide exposure, one would 
expect that the sensitizing effect will be limited to the 
tumor as soon as the radionuclide has been cleared 
from circulation. It will be pivotal to monitor the effect 
of PARP inhibition in combination with PRRT closely 
in an in vivo model to optimize the timing of the 
combination regimen in order to reach maximum 
effect on the tumor and minimal normal tissue 
damage. Interestingly, triple combination treatment 
experiments in triple-negative breast cancer and 
pancreatic ductal adenocarcinoma xenograft models 
using radioimmunotherapy, chemotherapy and DDR 
inhibitors showed promising results in tumor 
eradication [21, 22]. 
We showed that the combination treatment 
increased the number of DSBs and, most interestingly, 
the breaks persisted for at least six days after 
treatment, whereas most DSBs were repaired within 
four days after 177Lu-DOTA-TATE monotherapy. 
Removal of the PARP inhibitor at day 4 after PRRT 
did not diminish the number of DSBs, indicating that 
they had been induced within the first 3 days after 
treatment and could not be repaired up to day 6 (even 
in the absence of the inhibitor). This implies that only 
a short treatment with the PARP inhibitor after PRRT 
is needed to obtain the favorable results. For patients 
this would mean that a brief treatment with the PARP 
inhibitor would be sufficient, minimizing the possibly 
enhanced side effects and reducing treatment costs. 
Here we provided evidence of the sensitization 
of SSTR2-expressing human tumor cells and NET 
tissue slices to PRRT using the PARP inhibitor 
Olaparib. The knowledge gained in this study will 
also be applicable to other tumors that can be treated 
with PRRT, for example prostate tumors expressing 
the prostate specific membrane antigen (PSMA) [23]. 
Radionuclide treatment of PSMA-positive tumors is 
currently in clinical trials [24]. We expect that results 
of this project will also impact on this and similar 
radionuclide therapy applications. As Olaparib has 
been approved by the FDA and EMA, its application 
in PRRT in the clinic would be relatively easy and 
could be achieved in the near future. 
Conclusion 
In this study, we show that the innovative 
combination of sensitizing SSTR2-expressing human 
tumor cells to PRRT using the PARP inhibitor 
Olaparib; the combination treatment increased 
genotoxic stress and cell death and thereby has the 
potential to augment current PRRT outcomes without 
extra harm to healthy tissue. 
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